Tempus Platform
AI-enabled precision medicine platform for oncology and other diseases
Platform · Cloud SaaSCompany source
Company profile
About Tempus
Tempus uses data and AI to create precision medicine services, including diagnostics for oncology, cardiology, radiology, and more.
Company description Tempus official website
Primary marketPrecision Medicine & Genomics
Commercial modelCommercial information available on request
Company presenceLinkedIn
Work at Tempus?
Claim this listing Claim this profile to manage Company information and connect with the Health AI Central audience.
01 · Operating footprint
Where the Company operates
Company-profile context for clinical focus, customers, deployment, integration, milestones, and partnerships.
Clinical focus
- oncology
Who it serves
- providers
Deployment & integration
Cloud Saas deployment with recorded integration context.
Geographic context
MarketsNot currently listed
Company sourceOfficial website
02 · Flagship portfolio
Products, workflows, and platform capabilities
Selected source-backed Company products and the available commercial context.
03 · Research intelligence
Research Intelligence evidence
Publications, preprints, clinical validation, and regulatory records in Evidence Position order.
Evidence position
Publications, clinical validation, and regulatory records connected to this Company appear here.
Research
Publications & preprints
Genomic and Transcriptomic Correlates of Deep PSA Response in Patients with Metastatic Androgen Pathway Modulation-Sensitive Prostate Cancer.The oncologist · Sep 17, 2026
scDiagnostics: systematic assessment of cell type annotation in single-cell transcriptomics data.Briefings in bioinformatics · Sep 1, 2026
EGFR S442 ectodomain mutation confers cetuximab resistance that can be overcome by ERBB2 blockade with trastuzumab-deruxtecan.Cancer letters · Aug 28, 2026
Authors' reply to Detection yield, not positive predictive value, is the relevant metric for screening claims.Heart rhythm · Aug 27, 2026
Tumor Mutational Burden and Clinical Outcomes in Muscle-Invasive Bladder Cancer Patients Treated with Neoadjuvant Chemotherapy.Cancer research communications · Aug 13, 2026
Molecular and Immune Correlates of Lymphocyte Activation Gene-3 Expression in Renal Cell Carcinoma.The oncologist · Aug 11, 2026
Clinical validation
Clinical-trial records
Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell ManufacturingNCT04981119 · Sponsor · RECRUITING
A Longitudinal Multi-Omic Biomarker Profiling Study of Patients With Head & Neck Squamous Cell Carcinoma (HNSCC)NCT06163534 · Sponsor · RECRUITING
Evaluating Minimal Residual Disease (MRD) Through Longitudinal Circulating Tumor DNA (ctDNA) Profiling in Breast MalignanciesNCT07211178 · Sponsor · RECRUITING
Multi-site Study of the Clinical Impact of an AI-assisted Approach to Referring Patients With Interstitial Lung Disease for Diagnostic Evaluation of Pulmonary HypertensionNCT06911632 · Sponsor · RECRUITING
A Longitudinal Multi-Center Molecular Biomarker Discovery Registry for Patients With Hematologic MalignanciesNCT07154823 · Sponsor · RECRUITING
NOrthwestern Tempus AI-enaBLed Electrocardiography (NOTABLE) TrialNCT06511505 · Sponsor · RECRUITING
Regulatory
Regulatory records
No linked records are currently available.
04 · Company-reported outcomes
Outcomes and case studies
Company-reported outcomes and customer stories are distinct from linked Research Intelligence evidence.
No Company-reported outcomes are currently listed.
05 · Leadership
Leadership team
Leadership profiles and professional links from the current Company record.
No active leadership profiles are currently listed.
06 · Company updates
Updates from Tempus
Recent articles published on Tempus's official website.
No Company updates are currently listed.
07 · HAIC coverage
Coverage and analysis
Health AI Central reporting that mentions this Company.
08 · Official presence
Company sources and channels
Curated official destinations from the active Company record.
09 · Market pathway
Additional Companies in this Market
Other active Companies in the same market, selected alphabetically from the HAIC directory.
Market context
Precision Medicine & Genomics
Companies using AI to analyze genomic, proteomic, metabolomic, or multi-omics data to provide personalized treatment recommendations, identify genetic risks, or develop targeted therapies. Includes genomic sequencing platforms with AI analysis, preventive medicine based on genetic risk assessment, and longevity care based on molecular and genetic data.
Explore the full market directory or compare this Company with additional active profiles.
View all Companies in this market
10 · Pro research
Coming soon
Expanded Company research is in development.
Health AI Central Pro · Coming Soon
Deeper Company research is coming soon.
Pro Research will introduce expanded technical context, linked evidence analysis, and comparative Company research.
Linked research, clinical, and regulatory source pathways.
Expanded product, deployment, integration, and partnership research.
Record-level provenance and review context.